Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cytokinetics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://www.cytokinetics.com
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Robert I. Blum, MBA
Number Of Employees: 498
Enterprise Value: $4,979,780,160
PE Ratio: -7.17
Exchange/Ticker 1: NASDAQ:CYTK
Exchange/Ticker 2: N/A
Latest Market Cap: $4,481,856,512
BioCentury | Nov 26, 2024
Deals
Kyowa Kirin brings global reach to Kura’s menin program via licensing deal
Also in BioCentury’s Deals Report: Novartis buys gene therapy play Kate, Telix buys FAP-targeting theranostics, and more
BioCentury | Oct 25, 2024
Deals
James Sabry on industry-shaping changes in innovation and deal-making
Business development veteran talks to BioCentury as he transitions from Roche to BioMarin, entering the one biotech segment he’s not yet been in
BioCentury | Aug 22, 2024
Management Tracks
Blank slate at BioMarin for Sabry as dealmaker gets back to biotech
Company also adds Friberg to lead R&D, continuing the rebuild of its leadership team with former Genentech, Roche, Amgen execs
BioCentury | May 28, 2024
Management Tracks
Dealmaker Sabry retiring from Roche after 14-year stint
Pharma has struck multiple 10-figure deals under Sabry’s watch, expands role for BD head Boris Zaitra
BioCentury | May 24, 2024
Finance
Public Equity Report: Investors see Cytokinetics’ moves as doubt for M&A
Plus: IPO updates from Sunho, Rapport; Bicycle’s massive PIPE; Dyne’s opportunistic follow-on; and more
BioCentury | Feb 8, 2024
Product Development
Bristol Myers’ growing challenge
The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff
BioCentury | Feb 1, 2024
Deals
Narasimhan: Novartis prefers smaller deals amid search for high-value assets
‘No change’ to strategy of seeking bolt-ons worth $5B or less, suggesting Cytokinetics takeout is unlikely
BioCentury | Jan 13, 2024
Finance
JPM wrap: a BioCentury podcast
Takeouts, neuroscience innovation and investor sentiment to kick off 2024
BioCentury | Jan 12, 2024
Data Byte
Cytokinetics’ M&A roller-coaster
M&A target ends week without a buyer
BioCentury | Jan 5, 2024
Deals
Biotech M&A, innovation, public policy in 2024: BioCentury’s latest podcast
Takeout trends, JPM sentiment, innovation drivers & Washington preview
Items per page:
1 - 10 of 349